Mark Karwal
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
-
- Lung Cancer Research Studies
- Viral-associated cancers and disorders
Papers in
- Hepatology 11
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Liver physiology and pathology 4
- Oncology 10
- Cancer Immunotherapy and Biomarkers 3
- Cancer Treatment and Pharmacology 2
- Co-authors
- Seán Murphy (1 shared paper)M.A. Nathan (1 shared paper)Richard S. Finn (7 shared papers)Joong‐Won Park (1 shared paper)Fuad Ismail (1 shared paper)Melanie B. Thomas (1 shared paper)Ian Walters (1 shared paper)Jean‐Luc Raoul (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)Cancer Biotherapy and Radiopharmaceuticals (2 papers)Journal of Hepatology (2 papers)Annals of Oncology (2 papers)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Mark Karwal
21 papers receiving 302 citations
Peers
Comparison fields: 5 of 39
- Hepatology 122
- Oncology 120
- Pathology and Forensic Medicine 71
- Neurology 52
- Epidemiology 103
Countries citing papers authored by Mark Karwal
This map shows the geographic impact of Mark Karwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Karwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Karwal more than expected).
Fields of papers citing papers by Mark Karwal
This network shows the impact of papers produced by Mark Karwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Karwal. The network helps show where Mark Karwal may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Karwal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 119 | |
| 2 | Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. | 2003 | 55 |
| 3 | FDG-PET appearance of pelvic Castleman's disease. | 1997 | 43 |
| 4 | 2004 | 18 | |
| 5 | 2021 | 16 | |
| 6 | 2003 | 12 | |
| 7 | 2011 | 9 | |
| 8 | 2010 | 7 | |
| 9 | 2019 | 7 | |
| 10 | 2021 | 6 | |
| 11 | 2021 | 6 | |
| 12 | 2009 | 4 | |
| 13 | 2019 | 3 | |
| 14 | 2008 | 3 | |
| 15 | 2020 | 2 | |
| 16 | 2024 | 2 | |
| 17 | 2021 | 1 | |
| 18 | 2022 | 1 | |
| 19 | 2021 | 1 | |
| 20 | 2020 | 1 |
About Mark Karwal
Mark Karwal is a scholar working on Hepatology, Oncology, Epidemiology, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 21 papers that have together received 317 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Liver physiology and pathology (4 papers), Neuroendocrine Tumor Research Advances (3 papers), Liver Disease Diagnosis and Treatment (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer Treatment and Pharmacology (2 papers), Neuroblastoma Research and Treatments (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Hepatology (122 citations), Oncology (120 citations), Pathology and Forensic Medicine (71 citations), Neurology (52 citations) and Epidemiology (103 citations). Mark Karwal has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Seán Murphy, M.A. Nathan, Richard S. Finn, Joong‐Won Park, Fuad Ismail, Melanie B. Thomas, Ian Walters, Jean‐Luc Raoul, Christine Baudelet and Yusuf Menda. Their work appears in journals such as Journal of Clinical Oncology, Cancer Biotherapy and Radiopharmaceuticals, Journal of Hepatology, Annals of Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.